GFH018

Overview

GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC 50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer , breast cancer , and relapsed/metastatic nasopharyngeal carcinoma.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TGF-β Receptor | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-160215
• CAS No.: 2169299-67-4
• Molecular Formula: C21H19N7O
• Molecular Weight: 385.42
• Purity: 98.59%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (12.97 mM); Clear solution
• Availability: In-stock

Source

Original product source